Form 4: Cocrystal Pharma CEO Receives Stock Options

Cocrystal Pharma, Inc. reports the grant of stock options to CEO James Sapirstein under the 2025 Equity Incentive Plan.

Summary

• James Sapirstein, Chief Executive Officer of Cocrystal Pharma, Inc., was granted 235,000 stock options on June 3, 2026.
• These options have an exercise price of $1.12 per share and are exercisable starting June 3, 2026, with an expiration date of June 3, 2036.
• The options vest in four equal annual installments, beginning on June 3, 2027, contingent upon continued employment.
• Vesting may be accelerated upon a Change in Control or termination for Cause, as defined in the 2025 Equity Incentive Plan.
• The grant was approved by the Issuer's Board of Directors and is exempt from Section 16(b) of the Securities Exchange Act of 1934 under Rule 16b-3.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily details routine executive compensation rather than significant financial performance or strategic shifts.

Positives

• Grant of stock options to the CEO, aligning executive incentives with company performance.
• The grant is structured with a vesting schedule, encouraging long-term commitment.
• Potential for accelerated vesting upon significant corporate events like a Change in Control.

Negatives

• The filing does not provide specific financial performance data, making it difficult to assess the immediate impact of the option grant on the company's financial health.

Risks

• The value of the stock options is directly tied to the future performance of Cocrystal Pharma's stock price.
• Vesting is contingent on continued employment, meaning the options could be forfeited if employment is terminated before vesting dates.
• Potential for accelerated vesting upon a Change in Control could lead to dilution or changes in ownership structure.

Future Outlook

The future outlook for the stock options is dependent on the company's stock performance and the executive's continued employment. Vesting is scheduled over four years, with potential acceleration events.

Management Comments

• The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Board of Directors.
• The options were granted under the Issuer's 2025 Equity Incentive Plan and the exercisability of the options is subject to execution of the Issuer's standard form of Stock Option Agreement.
• The options vest in four equal annual installments, with the first such installment to vest on June 3, 2027, subject in each case to continued employment with the Issuer on the applicable vesting date and subject to potential accelerated vesting upon a Change in Control or termination for Cause, as such terms are defined in the 2025 Equity Incentive Plan.

Industry Context

StockSavvy.ai notes that the granting of stock options to senior executives is a common practice in the biotechnology and pharmaceutical sectors to attract, retain, and motivate key talent, aligning their interests with long-term shareholder value.

Corporate Governance

Related Party Transactions

• The filing details a transaction between the issuer (Cocrystal Pharma, Inc.) and its Chief Executive Officer, James Sapirstein, involving the grant of stock options.

Stakeholder Impact

• Shareholders: The stock option grant aligns executive interests with shareholder value, but the ultimate impact depends on future stock performance. Potential dilution if options are exercised.
• Employees: The 2025 Equity Incentive Plan provides a framework for future compensation, potentially motivating other employees if similar plans are extended.
• Management: Directly benefits CEO James Sapirstein through potential future gains on stock options.

Next Steps

• Continued employment of James Sapirstein to meet vesting requirements.
• Monitoring of Cocrystal Pharma's stock performance to determine the value of the stock options.
• Potential acceleration of vesting upon a Change in Control or termination for Cause.

Key Dates

Keywords

stock options, executive compensation, Cocrystal Pharma, COCP, James Sapirstein, equity incentive plan, Section 16 filing, Form 4